Cleveland-based Sator Therapeutics develops naturally occurring, non-pathogenic oncolytic viruses intended to selectively kill cancer cells in hard-to-treat tumors. Its preclinical platform combines a library of nearly 30 human enterovirus strains with systemic delivery, sequential dosing, companion diagnostics, and a patented dendritic-cell carrier. The company’s approach is protected by four issued U.S. patents and a Japanese patent, while its lead mesothelioma program advances toward formal clinical development.
Abeona Therapeutics IncAbeona Therapeutics is a commercial-stage biopharmaceutical company developing and delivering cell and gene therapies for serious diseases, with its Cleveland, Ohio facility serving as the commercial manufacturing site for ZEVASKYN®, approved in April 2025. The company combines ex vivo gene therapy and viral-vector expertise with a developing PSMA-targeted synthetic immune receptor T-cell therapy for advanced prostate cancer. Its fully integrated manufacturing model keeps critical production steps in-house, supporting supply and consistency for patients with rare disease.CLEVELAND, OH
AdaptimmuneAdaptimmune develops engineered T-cell receptor (TCR) therapies designed to direct the immune system against cancer, with a particular focus on solid tumors. Based in Oxfordshire, the company has built its platform over more than 15 years to identify cancer targets, enhance T-cell receptor affinity and screen candidates for potential off-target binding.541714PHILADELPHIA, PA
Facili Bio LLCFacili Bio LLC uses an AI-powered drug-discovery platform and proprietary computational biology to develop new cancer treatments. The company focuses on difficult areas of oncology, pairing research into patient-specific therapies with clinical studies intended to move promising discoveries toward patients.ALBANY, NY
Modulation TherapeuticsFounded in 2011 as a Moffitt Cancer Research Center spinoff, Modulation Therapeutics is a Morgantown clinical-stage biotechnology company developing therapies for aggressive solid-tumor cancers and liver disease. Its research team combines targeted alpha radiotherapy with peptide and small-molecule drug development, including a therapy for metastatic melanoma that has received FDA Orphan Drug and Fast Track designations. The privately held company moved its primary operations to West Virginia in 2016 and works with West Virginia University researchers to advance its pipeline toward clinical use.MORGANTOWN, WV